Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 2/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21525096 | 0.90 | GALR3 (0.33) | GALR3NR2F2PDE4APDE4BPDE4C | |
| SCHEMBL21525079 | 0.89 | GALR3 (0.32) | GALR3NR2F2PDE4APDE4BPDE4C | |
| SCHEMBL4845170 | 0.89 | GALR3 (0.40) | GALR3NR2F2LMNAPDE4APDE4B | |
| SCHEMBL4835831 | 0.87 | TK1 (0.33) | LMNAMAPK1MEN1KMT2ATSHR | |
| SCHEMBL4838348 | 0.85 | GALR3 (0.36) | GALR3NR2F2LMNAPDE4APDE4B | |
| SCHEMBL4843173 | 0.84 | GALR3 (0.36) | GALR3NR2F2MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL4843194 | 0.82 | GALR3 (0.36) | GALR3NR2F2MAPTHTTKDM4E | |
| SCHEMBL4835671 | 0.82 | RAB9A (0.42) | LMNAMAPTSMN1; SMN2MAPK1HTT | |
| SCHEMBL4845126 | 0.82 | KMT2A (0.35) | GALR3NR2F2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4845137 | 0.82 | KMT2A (0.37) | GALR3NR2F2LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411065-B2 | Peptide nucleic acid monomers: diphenylmethyl, benzyl, alkylthioalkyl, or phenylthioalkyl esters of N-(1-[4-(2-benzothiazolyl-, 2-benzoxazolyl-, 2-benzofuranyl- or 2-benzothiophenyl-sulfonyl)-3-piperazinon-1-ylcarbonylmethyl]pyrimidon-4-yl)carbamic acids | PANAGENE, INC. (KR) | 2008-08-12 | — | — | US | disclosed |
| US-7371860-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7371859-B2 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2008-05-13 | — | — | US | disclosed |
| US-7179896-B2 | Method of making PNA oligomers | PANAGENE, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-7145006-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-12-05 | — | — | US | disclosed |
| US-7125994-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-10-24 | — | — | US | disclosed |
| US-20060030709-A1 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | PANAGENE, INC. (KR) | 2006-02-09 | — | — | US | disclosed |
| US-20060008835-A1 | PNA monomer and precursor | KIM SUNG K | 2006-01-12 | — | — | US | disclosed |
| US-20060003374-A1 | Method of making PNA oligomers | KIM SUNG K | 2006-01-05 | — | — | US | disclosed |
| US-20050283005-A1 | PNA monomer and precursor | KIM SUNG K | 2005-12-22 | — | — | US | disclosed |
| US-6969766-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-29 | — | — | US | disclosed |
| US-20050250785-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| US-20050250786-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2005-11-10 | — | — | US | disclosed |
| US-20030225252-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030709-A1 | Peptide nucleic acid monomers; 1-(4-(benzothiazolyl-, benzoxazolyl-, benzofuranyl-, and benzothiophenyl- sulfonyl)piperidin-3-one-1-ylcarbonylmethyl)adenines; suitable for automatic and parallel synthesis; increased yields | RNGTT, POLL, RNMT | GALR3 3761/4885NR2F2 3364/4885LMNA 975/4885 |
| US-20050283005-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | GALR3 2428/4885NR2F2 3993/4885LMNA 683/4885 |
| US-20050250785-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | GALR3 2428/4885NR2F2 3993/4885LMNA 683/4885 |
| US-20030225252-A1 | PNA monomer and precursor | PNISR, RNGTT, NCL | GALR3 2238/4885NR2F2 3367/4885LMNA 720/4885 |
| US-20060008835-A1 | PNA monomer and precursor | PNISR, RNGTT, POLL | GALR3 2428/4885NR2F2 3993/4885LMNA 683/4885 |
| US-20050250786-A1 | PNA monomer and precursor | PNISR, RNGTT, NPR1 | GALR3 2356/4885NR2F2 3847/4885LMNA 553/4885 |
| US-20060003374-A1 | Method of making PNA oligomers | RNGTT, POLL, PNISR | GALR3 1949/4885NR2F2 3790/4885LMNA 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.